Myocardial infarction (MI) initiates a cascade of biological changes ending in cardiac remodeling and heart failure. Recent studies have characterized transcriptional programs in post-infarct ...
Acute myocardial infarction (AMI) is the predominant factor contributing to global mortality rates 1. By 2030, the incidence of AMI is expected to reach 75 million cases 2. The epidemiology of AMI ...
The benefit of beta-blockers after myocardial infarction in patients with a preserved left ventricular ejection fraction (LVEF) is unclear. We conducted a meta-analysis at the individual-patient level ...
The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results